Analgesic effects of chemically synthesized NOD1 and NOD2 agonists in mice

Abstract

Intracellular nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, recognize the diaminopimelic acid (DAP)-containing peptide moiety and muramyldipeptide (MDP) moiety of bacterial peptidoglycan, respectively. Muramyldipeptide has been reported to exert analgesic activity to decrease the frequency of acetic acid-induced writhing movements in mice. In this study, we demonstrated the analgesic activities of NOD1 as well as NOD2 agonists. Intravenous injection of NOD2-agonistic MDP, 6-O-stearoyl-MDP (L18-MDP), and MDP-Lys (L18) exhibited analgesic activity at 10, 50, and 2.0 µg/head, respectively, in BALB/c mice. NOD1-Agonistic FK156 (D-lactyl-L-Ala-D-Glu-meso-DAP-L-Gly) and FK565 (heptanoyl-D-Glu-meso-DAP-D-Ala) were also analgesic at 50 µg/head and 1.0 µg/head, respectively. The analgesic effect of FK565 appeared from 30 min, reached maximum activity at 8 h, and continued until 24 h. The FK565 exhibited activity by various administration routes; intravenous, intraperitoneal, intramuscular, sublingual (1.0 µg/head each), subcutaneous, intragastric (oral), intragingival (10 µg/ head each) and intracerebroventricular (0.01 µg/head). The analgesic activity of FK565 was observed even in tumor necrosis factor (TNF)-α knockout, interleukin (IL)-1α/β double knockout, and their triple knockout mice. Naloxane, a non-selective antagonist for the opioid receptor, completely inhibited the analgesic effect of FK565. These findings suggest that NOD1 and NOD2 activation induces an analgesic effect via opioid receptors in a TNF-α and IL-1α/βindependent manner.

Keywords

NOD1 NOD2 FK565 MDP analgesic effect opioid

References

Seidl PH , Schleifer KH. (eds) Biological properties of peptidoglycan . Berlin: Walter de Gruyter, 1986; 1-436.

Stewart-Tull DES. Immunopotentiating activity of peptidoglycan and surface polymers. In: Stewart-Tull DES , Davies M. (eds) Immunology of the Bacterial Cell Envelope. Chichester: John Wiley, 1985; 47-89.

Ellouz F. , Adam A. , Ciorbaru R. , Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974 ; 59: 1317-1325.

Kotani S. , Watanabe Y. , Kinoshita F. et al. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. Biken J 1975; 18: 105-111.

Takada H. , Uehara A. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling. Curr Pharm Des 2006 ; 12: 4163-4172.

Inohara N. , Ogura Y. , Fontalba A. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem 2003; 278: 5509-5512.

Girardin SE , Boneca IG , Viala J. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872.

Chamaillard M. , Hashimoto M. , Horie Y. et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4: 702-707.

Girardin SE , Boneca IG , Carneiro LAM et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003; 300: 1584-1587.

10.

Fleck J. , Mock M. , Tytgat F. , Nauciel C. , Minck R. Adjuvant activity in delayed hypersensitivity of the peptidic part of bacterial peptidoglycans. Nature 1974; 250: 517-518.

11.

Schleifer KH , Kandler O. Peptidoglycan types of bacterial cell walls and their taxonomic implications . Bacteriol Rev 1972; 36: 407-477.

12.

Adam A. Muramylpeptides and analogues. In: Synthetic Adjuvants . New York: John Wiley, 1985; 1-58.

13.

Goto T. , Aoki H. The immunomodulatory activities of acylpeptides. In: Azuma I , Jollès G. (eds) Immunostimulants: Now and Tomorrow. Berlin: Springer, 1987; 99-108.

14.

Kitaura Y. , Nakaguchi O. , Takeno H. et al. N2-(γ-D-Glutamyl)meso-2(L),2’(D)-diaminopimelic acid as the minimal prerequisite structure of FK-156: its acyl derivatives with potent immunostimulating activity. J Med Chem 1982; 25: 335-337.

15.

Ogawa T. , Kotani S. Analgesic effects of N-acetylmuramyl-L-alanyl-D-isoglutamine in decreasing the acetic acid-induced abdominal-writhing response. Infect Immun 1987; 55: 494-496.

16.

Horák P. , Mašek K. Analgesic activity of two synthetic immunomodulators, muramyl dipeptide and adamantylamide dipeptide in mice and rats. Methods Find Exp Clin Pharmacol 1988 ; 10: 569-574.

17.

Tagawa Y. , Sekikawa K. , Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-γ-/- mice, but not in TNF-α-/- mice. J Immunol 1997 ; 159: 1418-1428.

18.

Horai R. , Asano M. , Sudo K. et al. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion . J Exp Med 1998; 187: 1463-1475.

19.

Czlonkowski A. , Stein C. , Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 1993; 242: 229-235.

20.

Sacerdote P. , Bianchi M. , Manfredi B. , Panerai AE Intracerebroventricular interleukin-1α increases immunocyte β-endorphin concentrations in the rat: involvement of corticotropin-releasing hormone, catecholamines, and serotonin. Endocrinology 1994; 135: 1346-1352.

21.

Nakamura H. , Nakanishi K. , Kita A. , Kadokawa T. Interleukin-1 induces analgesia in mice by a central action. Eur J Pharmacol 1988; 149: 49-54.

22.

Brownstein MJ A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA 1993; 90: 5391-5393.

23.

Akira S. , Uematsu S. , Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.

24.

Yirmiya R. , Rosen H. , Donchin O. , Ovadia H. Behavioral effects of lipopolysaccharide in rats: involvement of endogenous opioids. Brain Res 1994; 648: 80-86.